The latest news from academia, regulators
research labs and other things of interest
Posted: November 1, 2007
Arrowhead and Subsidiary, Unidym, to Present at the AeA Classic Financial Conference
(Nanowerk News) Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its Chairman and CEO, R. Bruce Stewart, will present at the AeA Classic Financial Conference, Session II, in Monterey on Tuesday, November 6, and Wednesday, November 7, 2007. Mr. Stewart’s presentation entitled “Nanotechnology: Here and Now” will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences.
In addition, Arthur L. Swift, President and CEO of Unidym, Inc., will be giving a presentation entitled “Nanotechnology in the Post-Silicon Era.” Unidym is one of Arrowhead’s five majority-owned subsidiaries and produces a conductive, transparent film using networks of carbon nanotubes. This film has immediate application and advantages in touch screens and flat panel displays, as well as potential for thin film solar, fuel cells and printed electronics. Unidym owns the leading patent portfolio for carbon nanotube technology and production and is a leading manufacturer of pure carbon nanotubes that are supplied to a variety of researchers and product developers.
AeA is the largest association of high-tech companies in the United States with approximately 2,500 companies representing all segments of the industry and 1.8 million employees. The Classic Financial Conference continues to provide member public technology companies with an environment in which to showcase their companies to key technology investors.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
About Unidym, Inc.
Unidym (www.unidym.com) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal and mechanical properties. Unidym provides bulk materials, CNT-enabled products and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing, as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing a cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym’s licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.